About: Comparative safety of vaccine adjuvants: a summary of current evidence and future needs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparative safety of vaccine adjuvants: a summary of current evidence and future needs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparative safety of vaccine adjuvants: a summary of current evidence and future needs
Creator	Petrovsky, Nikolai
Source	Medline; PMC
abstract	Improved use of highly pure antigens to improve vaccine safety has led to reduced vaccine immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine immunogenicity. The ideal adjuvant should maximize vaccine immunogenicity without compromising tolerability or safety or posing undue risk. Unfortunately, adjuvant research has lagged behind other vaccine areas such as antigen discovery, with the consequence that only a very limited number of adjuvants based on aluminum salts, monophosphoryl lipid A and oil emulsions are currently approved for human use. Recent strategic initiatives to support adjuvant development by the National Institutes of Health should translate into greater adjuvant choices in the future. Mechanistic studies have been valuable in better understanding adjuvant action but mechanisms of adjuvant toxicity are less well understood. The inflammatory or danger-signal model of adjuvant action implies that increased vaccine reactogenicity is the inevitable price for improved immunogenicity. Hence, adjuvant reactogenicity may be avoidable only if it is possible to separate inflammation from adjuvant action. The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions such as narcolepsy, macrophagic myofasciitis or Alzheimer’s disease. While existing adjuvants based on aluminum salts have a strong safety record, there is an ongoing need for new adjuvants and for more intensive research into adjuvants and their effects.
has issue date	2015-10-08(xsd:dateTime)
bibo:doi	10.1007/s40264-015-0350-4
bibo:pmid	26446142
has license	green-oa
sha1sum (hex)	fddd6083ae049444ab80313b1093834d6949d211
schema:url	https://doi.org/10.1007/s40264-015-0350-4
resource representing a document's title	Comparative safety of vaccine adjuvants: a summary of current evidence and future needs
has PubMed Central identifier	PMC4615573
has PubMed identifier	26446142
schema:publication	Drug Safety
resource representing a document's body	covid:fddd6083ae049444ab80313b1093834d6949d211#body_text
is schema:about of	named entity 'toxicity' named entity 'effects' named entity 'discovery' named entity 'vaccine' named entity 'adjuvant' named entity 'improve' named entity 'COMPARATIVE' named entity 'USE' named entity 'ANTIGEN' named entity 'ACTION' named entity 'NATIONAL INSTITUTES OF HEALTH' named entity 'EFFICACY' named entity 'IMMUNOGENICITY' named entity 'MECHANISTIC STUDIES' named entity 'NEED FOR' named entity 'BETTER' named entity 'STRONG' named entity 'POTENTIAL' named entity 'RARE' named entity 'CONSEQUENCE' named entity 'HAVE' named entity 'FIELD' named entity 'ONGOING' named entity 'UNDERSTANDING' named entity 'MAY BE' named entity 'ADJUVANT' named entity 'POSING' named entity 'EFFECTS' named entity 'TO SEPARATE' named entity 'BUT' named entity 'ALZHEIMER' named entity 'UNDERSTOOD' named entity 'CURRENTLY' named entity 'POSSIBLE' named entity 'REMAINING' named entity 'EVIDENCE' named entity 'MODEL OF' named entity 'CHOICES' named entity 'NEEDS' named entity 'SAFETY' named entity 'ADJUVANTS' named entity 'NEW' named entity 'IMPROVED' named entity 'VACCINE' named entity 'TOLERABILITY' named entity 'RISK' named entity 'OIL' named entity 'RECORD' named entity 'ALUMINUM SALTS' named entity 'GREATER' named entity 'RELATIONSHIP' named entity 'LED' named entity 'FUTURE' named entity 'PURE' named entity 'IDEAL' named entity 'TRANSLATE' named entity 'USE OF' named entity 'PRICE' named entity 'STRATEGIC' named entity 'TO SUPPORT' named entity 'AREAS' named entity 'NUMBER OF' named entity 'DISEASE' named entity 'ADVERSE REACTIONS' named entity 'BASED' named entity 'RECENT' named entity 'DECIPHER' named entity 'DEVELOPMENT' named entity 'VACCINE' named entity 'RESEARCH' named entity 'SAFETY' named entity 'REDUCED' named entity 'ADJUVANTS' named entity 'MECHANISMS' named entity 'EMULSIONS' named entity 'MACROPHAGIC MYOFASCIITIS' named entity 'SIGNAL' named entity 'INCREASED' named entity 'ANTIGENS' named entity 'CHALLENGE' named entity 'HIGHLY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software